Gene expression profiling in rodent models for schizophrenia

Current Neuropharmacology

Volumn 8, Issue 4, 2010, Pages 382-393

  van Schijndel, Jessica E ^a   Martens, Gerard J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; Behavior; Genetics; Microarray; MRNA expression; Neurodevelopment; Pharmacology

Indexed keywords

EID: 84861321833     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015910793358132     Document Type: Article

References (121)

1. Rehn, A.E.; Rees, S.M. Investigating the neurodevelopmental hypothesis of schizophrenia. Clin. Exp. Pharmacol. Physiol., 2005, 32(9), 687-696.
2. Weinberger, D.R. From neuropathology to neurodevelopment. Lancet, 1995, 346(8974), 552-557.
3. AmericanPsychiatricAssociation. Diagnostic and statistical manual of mental disorders (4th ed.). American Psychiatric Publishing, Inc.: Arlington, 1994.
4. Keefe, R.S.; Fenton, W.S. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr. Bull, 2007, 33(4), 912-920.
5. Mueser, K.T.; McGurk, S.R. Schizophrenia. Lancet, 2004, 363(9426), 2063-2072.
6. Read, J.; Fink, P.J.; Rudegeair, T.; Felitti, V.; Whitfield, C.L. Child Maltreatment and Psychosis: A Return to a Genuinely Integrated Bio-Psycho-Social Model. Clin. Schizophrenia Related Psychoses, 2008, 7, 235-254.
7. Read, J.; van Os, J.; Morrison, A.P.; Ross, C.A. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatr. Scand., 2005, 112(5), 330-350.
8. Maki, P.; Veijola, J.; Jones, P.B.; Murray, G.K.; Koponen, H.; Tienari, P.; Miettunen, J.; Tanskanen, P.; Wahlberg, K.E.; Koskinen, J.; Lauronen, E.; Isohanni, M. Predictors of schizophrenia--a review. Br. Med. Bull., 2005, 73-74, 1-15.
9. Read, J.; Bentall, R.P.; Fosse, R. Time to abandon the bio-bio-bio model of psychosis: Exploring the epigenetic and psychological mechanisms by which adverse life events lead to psychotic symptoms. Epidemiol. Psichiatr. Soc., 2009, 18(4), 299-310.
10. Weaver, I.C.; Cervoni, N.; Champagne, F.A.; D'Alessio, A.C.; Sharma, S.; Seckl, J.R.; Dymov, S.; Szyf, M.; Meaney, M.J. Epigenetic programming by maternal behavior. Nat. Neurosci., 2004, 7, 847-854.
11. McGuffin, P. Nature and nurture interplay: schizophrenia. Psychiatr. Prax, 2004, 31(Suppl 2), S189-193.
12. Cardno, A.G.; Gottesman, II Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am. J. Med. Genet., 2000, 97(1), 12-17.
13. Lewis, C.M.; Levinson, D.F.; Wise, L.H.; DeLisi, L.E.; Straub, R.E.; Hovatta, I.; Williams, N.M.; Schwab, S.G.; Pulver, A.E.; Faraone, S.V.; Brzustowicz, L.M.; Kaufmann, C.A.; Garver, D.L.; Gurling, H.M.; Lindholm, E.; Coon, H.; Moises, H.W.; Byerley, W.; Shaw, S.H.; Mesen, A.; Sherrington, R.; O'Neill, F.A.; Walsh, D.; Kendler, K.S.; Ekelund, J.; Paunio, T.; Lonnqvist, J.; Peltonen, L.; O'Donovan, M.C.; Owen, M.J.; Wildenauer, D.B.; Maier, W.; Nestadt, G.; Blouin, J.L.; Antonarakis, S.E.; Mowry, B.J.; Silverman, J.M.; Crowe, R.R.; Cloninger, C.R.; Tsuang, M.T.; Malaspina, D.; Harkavy-Friedman, J.M.; Svrakic, D.M.; Bassett, A.S.; Holcomb, J.; Kalsi, G.; McQuillin, A.; Brynjolfson, J.; Sigmundsson, T.; Petursson, H.; Jazin, E.; Zoega, T.; Helgason, T. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet., 2003, 73(1), 34-48.
14. Riley, B.; Kendler, K.S. Molecular genetic studies of schizophrenia. Eur. J. Hum. Genet., 2006, 14(6), 669-680.
15. Bentall, R.P.; Fernyhough, C. Social predictors of psychotic experiences: specificity and psychological mechanisms. Schizophr. Bull., 2008, 34(6), 1012-1020.
16. Ruggeri, M.; Tansella, M. The interaction between genetics and epidemiology: the puzzle and its pieces. Epidemiol. Psichiatr. Soc., 2009, 18(2), 77-80.
17. Gaebel, W.; Zielasek, J. The DSM-V initiative "deconstructing psychosis" in the context of Kraepelin's concept on nosology. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258(Suppl 2), 41-47.
18. Lipska, B.K.; Weinberger, D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology, 2000, 23(3), 223-239.
19. van den Buuse, M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull., 2010, 36(2), 246-270.
20. Marcotte, E.R.; Pearson, D.M.; Srivastava, L.K. Animal models of schizophrenia: a critical review. J. Psychiatry Neurosci., 2001, 26(5), 395-410.
21. Desbonnet, L.; Waddington, J.L.; O'Tuathaigh, C.M. Mutant models for genes associated with schizophrenia. Biochem. Soc. Trans., 2009, 37(Pt 1), 308-312.
22. Tordjman, S.; Drapier, D.; Bonnot, O.; Graignic, R.; Fortes, S.; Cohen, D.; Millet, B.; Laurent, C.; Roubertoux, P.L. Animal models relevant to schizophrenia and autism: validity and limitations. Behav. Genet., 2007, 37(1), 61-78.
23. Dalman, C.; Allebeck, P.; Gunnell, D.; Harrison, G.; Kristensson, K.; Lewis, G.; Lofving, S.; Rasmussen, F.; Wicks, S.; Karlsson, H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry, 2008, 165(1), 59-65.
24. Yudofsky, S.C. Contracting schizophrenia: lessons from the influenza epidemic of 1918-1919. JAMA, 2009, 301(3), 324-326.
25. Winter, C.; Reutiman, T.J.; Folsom, T.D.; Sohr, R.; Wolf, R.J.; Juckel, G.; Fatemi, S.H. Dopamine and serotonin levels following prenatal viral infection in mouse--implications for psychiatric disorders such as schizophrenia and autism. Eur. Neuropsychopharmacol., 2008, 18(10), 712-716.
26. Fatemi, S.H.; Reutiman, T.J.; Folsom, T.D.; Huang, H.; Oishi, K.; Mori, S.; Smee, D.F.; Pearce, D.A.; Winter, C.; Sohr, R.; Juckel, G. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr. Res., 2008, 99(1-3), 56-70.
27. Birchmeier, C. ErbB receptors and the development of the nervous system. Exp. Cell Res., 2009, 315(4), 611-618.
28. Eastwood, S.L.; Law, A.J.; Everall, I.P.; Harrison, P.J. The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. Mol. Psychiatry, 2003, 8(2), 148-155.
29. Suzuki, K.; Nakamura, K.; Iwata, Y.; Sekine, Y.; Kawai, M.; Sugihara, G.; Tsuchiya, K.J.; Suda, S.; Matsuzaki, H.; Takei, N.; Hashimoto, K.; Mori, N. Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophr. Res., 2008, 98(1-3), 148-156.
30. Fatemi, S.H.; Pearce, D.A.; Brooks, A.I.; Sidwell, R.W. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse, 2005, 57(2), 91-99.
31. Sanjuan, J.; Tolosa, A.; Gonzalez, J.C.; Aguilar, E.J.; Perez-Tur, J.; Najera, C.; Molto, M.D.; de Frutos, R. Association between FOXP2 polymorphisms and schizophrenia with auditory hallucinations. Psychiar. Genet., 2006, 16(2), 67-72.
32. Williams, B.L.; Yaddanapudi, K.; Kirk, C.M.; Soman, A.; Hornig, M.; Lipkin, W.I. Metallothioneins and zinc dysregulation contribute to neurodevelopmental damage in a model of perinatal viral infection. Brain Pathol., 2006, 16(1), 1-14.
33. Koenig, J.I.; Kirkpatrick, B.; Lee, P. Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology, 2002, 27(2), 309-318.
34. Kinnunen, A.K.; Koenig, J.I.; Bilbe, G. Repeated variable prenatal stress alters pre-and postsynaptic gene expression in the rat frontal pole. J. Neurochem., 2003, 86(3), 736-748.
35. Lipska, B.K.; Jaskiw, G.E.; Weinberger, D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology, 1993, 9(1), 67-75.
36. Lipska, B.K.; Weinberger, D.R. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox. Res., 2002, 4(5-6), 469-475.
37. Wong, A.H.; Lipska, B.K.; Likhodi, O.; Boffa, E.; Weinberger, D.R.; Kennedy, J.L.; Van Tol, H.H. Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. Schizophr. Res., 2005, 77(2-3), 261-270.
38. Palomo, T.; Kostrzewa, R.M.; Archer, T.; Beninger, R.J. Neurodevelopmental liabilities in schizophrenia and affective disorders. Neurotox. Res., 2002, 4(5-6), 397-408.
39. Kohda, K.; Jinde, S.; Iwamoto, K.; Bundo, M.; Kato, N.; Kato, T. Maternal separation stress drastically decreases expression of transthyretin in the brains of adult rat offspring. Int. J. Neuropsychopharmacol., 2006, 9(2), 201-208.
40. Coolen, M.W.; Van Loo, K.M.; Van Bakel, N.N.; Pulford, D.J.; Serneels, L.; De Strooper, B.; Ellenbroek, B.A.; Cools, A.R.; Martens, G.J. Gene dosage effect on gamma-secretase component Aph-1b in a rat model for neurodevelopmental disorders. Neuron, 2005, 45(4), 497-503.
41. Whitaker-Azmitia, P.; Zhou, F.; Hobin, J.; Borella, A. Isolationrearing of rats produces deficits as adults in the serotonergic innervation of hippocampus. Peptides, 2000, 21(11), 1755-1759.
42. Ibi, D.; Takuma, K.; Koike, H.; Mizoguchi, H.; Tsuritani, K.; Kuwahara, Y.; Kamei, H.; Nagai, T.; Yoneda, Y.; Nabeshima, T.; Yamada, K. Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J. Neurochem., 2008, 105(3), 921-932.
43. Bubenikova-Valesova, V.; Horacek, J.; Vrajova, M.; Hoschl, C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev., 2008, 32(5), 1014-1023.
44. Ikonomidou, C.; Bosch, F.; Miksa, M.; Bittigau, P.; Vockler, J.; Dikranian, K.; Tenkova, T.I.; Stefovska, V.; Turski, L.; Olney, J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science, 1999, 283(5398), 70-74.
45. Toyooka, K.; Usui, M.; Washiyama, K.; Kumanishi, T.; Takahashi, Y. Gene expression profiles in the brain from phencyclidine-treated mouse by using DNA microarray. Ann. N. Y. Acad. Sci., 2002, 965, 10-20.
46. Kaiser, S.; Foltz, L.A.; George, C.A.; Kirkwood, S.C.; Bemis, K.G.; Lin, X.; Gelbert, L.M.; Nisenbaum, L.K. Phencyclidineinduced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Neurobiol. Dis., 2004, 16(1), 220-235.
47. Takebayashi, H.; Yamamoto, N.; Umino, A.; Nishikawa, T. Developmentally regulated and thalamus-selective induction of leiomodin2 gene by a schizophrenomimetic, phencyclidine, in the rat. Int. J. Neuropsychopharmacol., 2009, 1-16.
48. Annetta, M.G.; Iemma, D.; Garisto, C.; Tafani, C.; Proietti, R. Ketamine: new indications for an old drug. Curr. Drug Targets, 2005, 6(7), 789-794.
49. Lowe, X.R.; Lu, X.; Marchetti, F.; Wyrobek, A.J. The expression of Troponin T1 gene is induced by ketamine in adult mouse brain. Brain Res., 2007, 1174, 7-17.
50. Chen, L.; Guo, Q.; Li, J.Y. Transcription factor Gbx2 acts cellnonautonomously to regulate the formation of lineage-restriction boundaries of the thalamus. Development, 2009, 136(8), 1317-1326.
51. De, S.; Turman, J.E., Jr. Krox-20 gene expression: influencing hindbrain-craniofacial developmental interactions. Arch. Histol. Cytol., 2005, 68(4), 227-234.
52. Basu, A. Involvement of protein kinase C-delta in DNA damageinduced apoptosis. J. Cell Mol. Med., 2003, 7(4), 341-350.
53. Wai, P.Y.; Kuo, P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res., 2004, 121(2), 228-241.
54. de Moraes, E.; Dar, N.A.; de Moura Gallo, C.V.; Hainaut, P. Crosstalks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int. J. Cancer, 2007, 121(5), 929-937.
55. Sheikh, M.S.; Hollander, M.C.; Fornance, A.J., Jr. Role of Gadd45 in apoptosis. Biochem. Pharmacol., 2000, 59(1), 43-45.
56. Kim, M.S.; Pak, Y.K.; Jang, P.G.; Namkoong, C.; Choi, Y.S.; Won, J.C.; Kim, K.S.; Kim, S.W.; Kim, H.S.; Park, J.Y.; Kim, Y.B.; Lee, K.U. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat. Neurosci., 2006, 9(7), 901-906.
57. Holt, R.I.; Peveler, R.C.; Byrne, C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabet. Med., 2004, 21(6), 515-523.
58. Woodruff, G.N.; Foster, A.C.; Gill, R.; Kemp, J.A.; Wong, E.H.; Iversen, L.L. The interaction between MK-801 and receptors for Nmethyl-D-aspartate: functional consequences. Neuropharmacology, 1987, 26(7B), 903-909.
59. Nesic, O.; Svrakic, N.M.; Xu, G.Y.; McAdoo, D.; Westlund, K.N.; Hulsebosch, C.E.; Ye, Z.; Galante, A.; Soteropoulos, P.; Tolias, P.; Young, W.; Hart, R.P.; Perez-Polo, J.R. DNA microarray analysis of the contused spinal cord: effect of NMDA receptor inhibition. J. Neurosci. Res., 2002, 68(4), 406-423.
60. Feng, Z.; Davis, D.P.; Sasik, R.; Patel, H.H.; Drummond, J.C.; Patel, P.M. Pathway and gene ontology based analysis of gene expression in a rat model of cerebral ischemic tolerance. Brain Res., 2007, 1177, 103-123.
61. Marvanova, M.; Lakso, M.; Wong, G. Identification of genes regulated by memantine and MK-801 in adult rat brain by cDNA microarray analysis. Neuropsychopharmacology, 2004, 29(6), 1070-1079.
62. Matsuoka, T.; Tsunoda, M.; Sumiyoshi, T.; Takasaki, I.; Tabuchi, Y.; Seo, T.; Tanaka, K.; Uehara, T.; Itoh, H.; Suzuki, M.; Kurachi, M. Effect of MK-801 on gene expressions in the amygdala of rats. Synapse, 2008, 62(1), 1-7.
63. Howes, O.D.; Kapur, S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr. Bull., 2009, 35(3), 549-562.
64. Depatie, L.; Lal, S. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? J. Psychiatry Neurosci., 2001, 26(3), 203-220.
65. Ellenbroek, B.A.; Sluyter, F.; Cools, A.R. The role of genetic and early environmental factors in determining apomorphine susceptibility. Psychopharmacology (Berl), 2000, 148(2), 124-131.
66. Geyer, M.A. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry, 1998, 31(Suppl 2), 73-79.
67. Bymaster, F.P.; Rasmussen, K.; Calligaro, D.O.; Nelson, D.L.; DeLapp, N.W.; Wong, D.T.; Moore, N.A. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J. Clin. Psychiatry, 1997, 58(Suppl 10), 28-36.
68. Tarazi, F.I.; Baldessarini, R.J.; Kula, N.S.; Zhang, K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther., 2003, 306(3), 1145-1151.
69. Fatemi, S.H.; Reutiman, T.J.; Folsom, T.D.; Bell, C.; Nos, L.; Fried, P.; Pearce, D.A.; Singh, S.; Siderovski, D.P.; Willard, F.S.; Fukuda, M. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology, 2006, 31(9), 1888-1899.
70. Duncan, C.E.; Chetcuti, A.F.; Schofield, P.R. Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. Psychiatr. Genet., 2008, 18(5), 226-239.
71. Saito, A.; Fujikura-Ouchi, Y.; Kuramasu, A.; Shimoda, K.; Akiyama, K.; Matsuoka, H.; Ito, C. Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia. Neurosci. Lett., 2007, 411(3), 168-173.
72. Passos Gregorio, S.; Gattaz, W.F.; Tavares, H.; Kieling, C.; Timm, S.; Wang, A.G.; Berg Rasmussen, H.; Werge, T.; Dias-Neto, E. Analysis of coding-polymorphisms in NOTCH-related genes reveals NUMBL poly-glutamine repeat to be associated with schizophrenia in Brazilian and Danish subjects. Schizophr. Res., 2006, 88(1-3), 275-282.
73. Qin, W.; Gao, J.; Xing, Q.; Yang, J.; Qian, X.; Li, X.; Guo, Z.; Chen, H.; Wang, L.; Huang, X.; Gu, N.; Feng, G.; He, L. A familybased association study of PLP1 and schizophrenia. Neurosci. Lett., 2005, 375(3), 207-210.
74. Petryshen, T.L.; Middleton, F.A.; Tahl, A.R.; Rockwell, G.N.; Purcell, S.; Aldinger, K.A.; Kirby, A.; Morley, C.P.; McGann, L.; Gentile, K.L.; Waggoner, S.G.; Medeiros, H.M.; Carvalho, C.; Macedo, A.; Albus, M.; Maier, W.; Trixler, M.; Eichhammer, P.; Schwab, S.G.; Wildenauer, D.B.; Azevedo, M.H.; Pato, M.T.; Pato, C.N.; Daly, M.J.; Sklar, P. Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia. Mol. Psychiatry, 2005, 10(12), 1074-1088, 1057.
75. Novak, G.; Kim, D.; Seeman, P.; Tallerico, T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Res. Mol. Brain Res., 2002, 107(2), 183-189.
76. Kontkanen, O.; Toronen, P.; Lakso, M.; Wong, G.; Castren, E. Antipsychotic drug treatment induces differential gene expression in the rat cortex. J. Neurochem., 2002, 83(5), 1043-1053.
77. Kroesen, S.; Marksteiner, J.; Mahata, S.K.; Mahata, M.; Fischer-Colbrie, R.; Saria, A.; Kapeller, I.; Winkler, H. Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain. Neuroscience, 1995, 69(3), 881-891.
78. Bauer, R.; Mayr, A.; Lederer, W.; Needham, P.L.; Kilpatrick, I.C.; Fleischhacker, W.W.; Marksteiner, J. Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs. Neuropsychopharmacology, 2000, 23(1), 46-55.
79. Kajimoto, Y.; Shirakawa, O.; Kuno, T.; Nishino, N.; Nakai, H. Delayed changes in neural visinin-like calcium-binding protein gene expression caused by acute phencyclidine administration. J. Neural Transm. Gen. Sect., 1995, 100(3), 257-262.
80. Takahashi, Y.; Kumanishi, T.; Hayashi, S. Using a DNA microarray method to examine gene expression in brain from clozapineinjected mice. Ann. N. Y. Acad. Sci., 2004, 1025, 561-569.
81. Mehler-Wex, C.; Grunblatt, E.; Zeiske, S.; Gille, G.; Rausch, D.; Warnke, A.; Gerlach, M. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J. Neural. Transm., 2006, 113(10), 1383-1393.
82. Taylor, D.M.; McAskill, R. Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr. Scand., 2000, 101(6), 416-432.
83. Cooper, G.D.; Harrold, J.A.; Halford, J.C.; Goudie, A.J. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(2), 428-436.
84. Feher, L.Z.; Kalman, J.; Puskas, L.G.; Gyulveszi, G.; Kitajka, K.; Penke, B.; Palotas, M.; Samarova, E.I.; Molnar, J.; Zvara, A.; Matin, K.; Bodi, N.; Hugyecz, M.; Pakaski, M.; Bjelik, A.; Juhasz, A.; Bogats, G.; Janka, Z.; Palotas, A. Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem. Int., 2005, 47(4), 271-280.
85. Chen, M.L.; Chen, C.H. Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology, 2005, 30(2), 268-277.
86. Chen, J.; Lipska, B.K.; Weinberger, D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol. Psychiatry, 2006, 59(12), 1180-1188.
87. Gainetdinov, R.R.; Mohn, A.R.; Caron, M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci., 2001, 24(9), 527-533.
88. Mohn, A.R.; Gainetdinov, R.R.; Caron, M.G.; Koller, B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell, 1999, 98(4), 427-436.
89. Spielewoy, C.; Roubert, C.; Hamon, M.; Nosten-Bertrand, M.; Betancur, C.; Giros, B. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol., 2000, 11(3-4), 279-290.
90. Miyamoto, Y.; Yamada, K.; Noda, Y.; Mori, H.; Mishina, M.; Nabeshima, T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J. Neurosci., 2001, 21(2), 750-757.
91. Zetterstrom, R.H.; Solomin, L.; Jansson, L.; Hoffer, B.J.; Olson, L.; Perlmann, T. Dopamine neuron agenesis in Nurr1-deficient mice. Science, 1997, 276(5310), 248-250.
92. Gil, M.; McKinney, C.; Lee, M.K.; Eells, J.B.; Phyillaier, M.A.; Nikodem, V.M. Regulation of GTP cyclohydrolase I expression by orphan receptor Nurr1 in cell culture and in vivo. J. Neurochem., 2007, 101(1), 142-150.
93. Kahler, A.K.; Djurovic, S.; Kulle, B.; Jonsson, E.G.; Agartz, I.; Hall, H.; Opjordsmoen, S.; Jakobsen, K.D.; Hansen, T.; Melle, I.; Werge, T.; Steen, V.M.; Andreassen, O.A. Association analysis of schizophrenia on 18 genes involved in neuronal migration: MDGA1 as a new susceptibility gene. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2008, 147B(7), 1089-1100.
94. Impagnatiello, F.; Guidotti, A.R.; Pesold, C.; Dwivedi, Y.; Caruncho, H.; Pisu, M.G.; Uzunov, D.P.; Smalheiser, N.R.; Davis, J.M.; Pandey, G.N.; Pappas, G.D.; Tueting, P.; Sharma, R.P.; Costa, E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. USA, 1998, 95(26), 15718-15723.
95. Grayson, D.R.; Chen, Y.; Costa, E.; Dong, E.; Guidotti, A.; Kundakovic, M.; Sharma, R.P. The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia. Pharmacol. Ther., 2006, 111(1), 272-286.
96. Tueting, P.; Costa, E.; Dwivedi, Y.; Guidotti, A.; Impagnatiello, F.; Manev, R.; Pesold, C. The phenotypic characteristics of heterozygous reeler mouse. Neuroreport, 1999, 10(6), 1329-1334.
97. Majumdar, A.; Nagaraj, R.; Banerjee, U. strawberry notch encodes a conserved nuclear protein that functions downstream of Notch and regulates gene expression along the developing wing margin of Drosophila. Genes Dev., 1997, 11(10), 1341-1353.
98. Baba, K.; Dekimoto, H.; Muraoka, D.; Agata, K.; Terashima, T.; Katsuyama, Y. A mouse homologue of Strawberry Notch is transcriptionally regulated by Reelin signal. Biochem. Biophys. Res. Commun., 2006, 350(4), 842-849.
99. Lindsay, E.A.; Botta, A.; Jurecic, V.; Carattini-Rivera, S.; Cheah, Y.C.; Rosenblatt, H.M.; Bradley, A.; Baldini, A. Congenital heart disease in mice deficient for the DiGeorge syndrome region. Nature, 1999, 401(6751), 379-383.
100. [100] Jurata, L.W.; Gallagher, P.; Lemire, A.L.; Charles, V.; Brockman, J.A.; Illingworth, E.L.; Altar, C.A. Altered expression of hippocampal dentate granule neuron genes in a mouse model of human 22q11 deletion syndrome. Schizophr. Res., 2006, 88(1-3), 251-259.
101. [101] Vawter, M.P.; Shannon Weickert, C.; Ferran, E.; Matsumoto, M.; Overman, K.; Hyde, T.M.; Weinberger, D.R.; Bunney, W.E.; Kleinman, J.E. Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem. Res., 2004, 29(6), 1245-1255.
102. [102] Barbier, E.; Zapata, A.; Oh, E.; Liu, Q.; Zhu, F.; Undie, A.; Shippenberg, T.; Wang, J.B. Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice. Neuropsychopharmacology, 2007, 32(8), 1774-1782.
103. [103] Kernie, S.G.; Liebl, D.J.; Parada, L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J., 2000, 19(6), 1290-1300.
104. [104] Lyons, W.E.; Mamounas, L.A.; Ricaurte, G.A.; Coppola, V.; Reid, S.W.; Bora, S.H.; Wihler, C.; Koliatsos, V.E.; Tessarollo, L. Brainderived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl. Acad. Sci. USA, 1999, 96(26), 15239-15244.
105. [105] Gorski, J.A.; Balogh, S.A.; Wehner, J.M.; Jones, K.R. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience, 2003, 121(2), 341-354.
106. [106] Wood, G.K.; Tomasiewicz, H.; Rutishauser, U.; Magnuson, T.; Quirion, R.; Rochford, J.; Srivastava, L.K. NCAM-180 knockout mice display increased lateral ventricle size and reduced prepulse inhibition of startle. Neuroreport, 1998, 9(3), 461-466.
107. [107] Ohshima, T.; Ward, J.M.; Huh, C.G.; Longenecker, G.; Veeranna; Pant, H.C.; Brady, R.O.; Martin, L.J.; Kulkarni, A.B. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. USA, 1996, 93(20), 11173-11178.
108. [108] Erbel-Sieler, C.; Dudley, C.; Zhou, Y.; Wu, X.; Estill, S.J.; Han, T.; Diaz-Arrastia, R.; Brunskill, E.W.; Potter, S.S.; McKnight, S.L. Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proc. Natl. Acad. Sci USA, 2004, 101(37), 13648-13653.
109. [109] Paylor, R.; Zhao, Y.; Libbey, M.; Westphal, H.; Crawley, J.N. Learning impairments and motor dysfunctions in adult Lhx5-deficient mice displaying hippocampal disorganization. Physiol. Behav., 2001, 73(5), 781-792.
110. [110] Gogos, J.A.; Santha, M.; Takacs, Z.; Beck, K.D.; Luine, V.; Lucas, L.R.; Nadler, J.V.; Karayiorgou, M. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat. Genet., 1999, 21(4), 434-439.
111. [111] Pletnikov, M.V.; Ayhan, Y.; Nikolskaia, O.; Xu, Y.; Ovanesov, M.V.; Huang, H.; Mori, S.; Moran, T.H.; Ross, C.A. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol. Psychiatry, 2008, 13(2), 173-186, 115.
112. [112] Li, W.; Zhou, Y.; Jentsch, J.D.; Brown, R.A.; Tian, X.; Ehninger, D.; Hennah, W.; Peltonen, L.; Lonnqvist, J.; Huttunen, M.O.; Kaprio, J.; Trachtenberg, J.T.; Silva, A.J.; Cannon, T.D. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. USA, 2007, 104(46), 18280-18285.
113. [113] Karl, T.; Duffy, L.; Scimone, A.; Harvey, R.P.; Schofield, P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav., 2007, 6(7), 677-687.
114. [114] Torres, G.; Hallas, B.H.; Vernace, V.A.; Jones, C.; Gross, K.W.; Horowitz, J.M. A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia. Brain Res. Bull., 2004, 62(4), 315-326.
115. [115] Tomita, H.; Shakkottai, V.G.; Gutman, G.A.; Sun, G.; Bunney, W.E.; Cahalan, M.D.; Chandy, K.G.; Gargus, J.J. Novel truncated isoform of SK3 potassium channel is a potent dominant-negative regulator of SK currents: implications in schizophrenia. Mol. Psychiatry, 2003, 8(5), 524-535, 460.
116. [116] Huffaker, S.J.; Chen, J.; Nicodemus, K.K.; Sambataro, F.; Yang, F.; Mattay, V.; Lipska, B.K.; Hyde, T.M.; Song, J.; Rujescu, D.; Giegling, I.; Mayilyan, K.; Proust, M.J.; Soghoyan, A.; Caforio, G.; Callicott, J.H.; Bertolino, A.; Meyer-Lindenberg, A.; Chang, J.; Ji, Y.; Egan, M.F.; Goldberg, T.E.; Kleinman, J.E.; Lu, B.; Weinberger, D.R. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat. Med., 2009, 15(5), 509-518.
117. [117] Horvath, S.; Mirnics, K. Breaking the gene barrier in schizophrenia. Nat. Med., 2009, 15(5), 488-490.
118. [118] Dampney, R.A.; Li, Y.W.; Hirooka, Y.; Potts, P.; Polson, J.W. Use of c-fos functional mapping to identify the central baroreceptor reflex pathway: advantages and limitations. Clin. Exp. Hypertens., 1995, 17(1-2), 197-208.
119. [119] Vahl, T.P.; Ulrich-Lai, Y.M.; Ostrander, M.M.; Dolgas, C.M.; Elfers, E.E.; Seeley, R.J.; D'Alessio, D.A.; Herman, J.P. Comparative analysis of ACTH and corticosterone sampling methods in rats. Am. J. Physiol. Endocrinol. Metab., 2005, 289(5), E823-828.
120. [120] Nakazato, K.; Yoshida, Y.; Takemori, K.; Kobayashi, K.; Sakamoto, A. Expressions of genes encoding drug-metabolizing enzymes are altered after sevoflurane, isoflurane, propofol or dexmedetomidine anesthesia. Biomed. Res., 2009, 30(1), 17-24.
121. [121] Culley, D.J.; Yukhananov, R.Y.; Xie, Z.; Gali, R.R.; Tanzi, R.E.; Crosby, G. Altered hippocampal gene expression 2 days after general anesthesia in rats. Eur. J. Pharmacol., 2006, 549(1-3), 71-78.